Wall Street Zen upgraded shares of Establishment Labs (NASDAQ:ESTA – Free Report) from a sell rating to a hold rating in a research report report published on Sunday.
Other equities analysts have also issued research reports about the stock. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research report on Tuesday, October 7th. Canaccord Genuity Group initiated coverage on shares of Establishment Labs in a research report on Wednesday, August 20th. They set a “buy” rating and a $60.00 price objective for the company. Mizuho raised their price objective on shares of Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Establishment Labs in a research report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Establishment Labs presently has a consensus rating of “Moderate Buy” and an average target price of $56.50.
Get Our Latest Stock Report on ESTA
Establishment Labs Stock Performance
Establishment Labs (NASDAQ:ESTA – Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). The company had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.80 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The business’s quarterly revenue was up 16.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.62) EPS. Establishment Labs has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Establishment Labs
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Simplify Asset Management Inc. purchased a new position in Establishment Labs during the 3rd quarter worth approximately $1,555,000. Brian Low Financial Group LLC purchased a new position in Establishment Labs during the 3rd quarter worth approximately $223,000. ARS Investment Partners LLC grew its position in Establishment Labs by 50.0% during the 3rd quarter. ARS Investment Partners LLC now owns 9,750 shares of the company’s stock worth $400,000 after purchasing an additional 3,250 shares in the last quarter. Guided Capital Wealth Management LLC grew its position in Establishment Labs by 3.8% during the 3rd quarter. Guided Capital Wealth Management LLC now owns 51,650 shares of the company’s stock worth $2,117,000 after purchasing an additional 1,908 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC grew its position in Establishment Labs by 5.8% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company’s stock worth $261,000 after purchasing an additional 350 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.
Establishment Labs Company Profile
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Recommended Stories
- Five stocks we like better than Establishment Labs
- Roth IRA Calculator: Calculate Your Potential Returns
- 2 Ways to Trade Qualcomm Ahead of November’s Earnings
- How to Most Effectively Use the MarketBeat Earnings Screener
- Lululemon: 2 Signs the Bottom Is In, and 1 Sign It Isn’t
- Overbought Stocks Explained: Should You Trade Them?
- Got 1K to Invest? These 3 Stocks Are Still Attractive Buys
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.